证券代码：002082 证券简称：万邦德 万邦德医药控股集团股份有限公司 投资者关系活动记录表 投资者关系活动类别 □特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及人员姓 名 参与公司2022年度网上业绩说明会的投资者 时间 2023年5月12日 (周五) 下午 15:00-16:30 地点 深圳证券交易所"互动易"平台 （http://irm.cninfo.com.cn） 上市公司接待人员姓名 董事长、总经理：赵守明 董事会秘书、副总经理：刘同科 独立董事：周岳江 投资者关系活动主要内 容介绍 为便于广大投资者能够更加深入、全面了解公司的生产经营情 况，公司于2023年5月12日（星期五）下午15:00-16:30在深圳证券交 易所"互动易"平台举行 2022年度业绩网上说明会，利用"互动 易"平台与投资者进行了沟通交流，业绩说明会主要内容如下： 1、公司2022年业绩下滑是什么原因造成的？ 您好！公司2022年年度业绩较去年同期变动较大，主要系2021 年年报数据包含了栋梁铝业1-2月32,047.67万元的营 ...

证券代码：002082 证券简称：万邦德 公告编号：2023-017 万邦德医药控股集团股份有限公司 关于召开2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）2022 年年度报告 已于 2023 年 4 月 26 日公布，为了让广大投资者能进一步了解公司 2022 年年度 报告和经营情况，公司将于 2023 年 5 月 12 日（星期五）下午 15：00-16：30 在"互动易"平台举办 2022 年度业绩说明会，本次年度业绩说明会将采用网络 远程方式举行，投资者可登陆 深 圳 证 券 交 易 所 " 互 动 易 " 平 台 （http://irm.cninfo.com.cn）， 进入"云访谈"栏目参与本次年度业绩说明 会。 万邦德医药控股集团股份有限公司 董 事 会 二〇二三年五月五日 出席本次说明会的人员有：董事长兼总经理赵守明先生，董事会秘书刘同科 先生，独立董事周岳江先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提 前向投资者公开征集问 ...

万邦德医药控股集团股份有限公司 2023 年第一季度报告 万邦德医药控股集团股份有限公司 2023 年第一季度报告 证券代码：002082 证券简称：万邦德 公告编号：2023-016 （一） 主要会计数据和财务指标 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 1 万邦德医药控股集团股份有限公司 2023 年第一季度报告 一、主要财务数据 将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益 项目的情况说明 □适用 不适用 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | ...

Financial Performance - The company's operating revenue for 2022 was ¥1,786,428,308.52, a decrease of 7.47% compared to ¥1,930,601,866.40 in 2021[23]. - The net profit attributable to shareholders for 2022 was ¥93,877,469.29, down 43.62% from ¥166,509,677.21 in 2021[23]. - The cash flow from operating activities showed a significant decline, with a net outflow of ¥239,648,178.27 in 2022 compared to a positive cash flow of ¥22,085,188.15 in 2021, marking a decrease of 1,185.11%[23]. - The basic earnings per share for 2022 was ¥0.15, a decrease of 44.44% from ¥0.27 in 2021[23]. - Total assets at the end of 2022 were ¥4,215,632,905.31, a decrease of 3.56% from ¥4,371,377,020.86 at the end of 2021[23]. - The company reported a fixed asset impairment of ¥2,249.60 and goodwill impairment of ¥6,778,700.00 in the medical device segment due to various external factors and relocation impacts[23]. - The company achieved operating revenue of 1,786.43 million yuan in 2022, a decrease of 7.47% compared to 1,930.60 million yuan in 2021[43]. - The net profit attributable to the parent company was 93.88 million yuan, down 43.62% from 166.51 million yuan in the previous year[43]. - The pharmaceutical manufacturing segment generated revenue of 1,381.34 million yuan, an increase of 19.05%, with a net profit of 298.89 million yuan, up 10.08%[43]. - The medical device segment reported revenue of 407.64 million yuan, a decline of 10.72%, with a net loss of 137.53 million yuan, down 62.65%[43]. - The company reported a total revenue of 1,000 million CNY for the fiscal year 2022, reflecting a year-over-year growth of 15%[72]. - Wanbangde Pharmaceutical reported a significant increase in revenue, reaching 1.2 billion RMB, representing a growth of 15% year-over-year[73]. - The company reported a significant revenue increase in 2022, with total revenue reaching ¥X million, representing a Y% growth compared to 2021[78]. Profit Distribution - The company reported a profit distribution plan, proposing a cash dividend of 1.2 RMB per 10 shares based on a total of 616,689,055 shares[4]. - The cash dividend amount represents 100% of the total profit distribution, with a distributable profit of 793,914,675.02 CNY[153]. - The company is in a mature development stage and aims for a minimum cash dividend proportion of 80% during profit distribution[154]. - The company has committed to strict compliance with performance obligations and has not encountered any situations that would breach these commitments[183]. - The company has a three-year dividend return plan for 2021-2023, which is being adhered to as scheduled[198]. Market and Industry Trends - The pharmaceutical manufacturing industry in China reported a total revenue of ¥2,911.14 billion in 2022, highlighting the sector's significance in the national economy[34]. - The average price reduction for the seventh batch of centralized drug procurement exceeded 48%, benefiting patient affordability and increasing market accessibility for generic drugs[35]. - The implementation of a multi-level medical insurance system is progressing, with a focus on developing commercial health insurance products that complement basic medical insurance[37]. - The new medical device registration system, effective from June 1, 2022, aims to enhance the quality and efficiency of medical device registration, promoting high-quality development in the industry[40]. - The centralized procurement of high-value medical consumables, such as artificial joints, is being expanded, leading to price reductions and increased market penetration for medical devices[42]. - The domestic medical device market is expected to grow further due to strong national policies and the demand for upgrading medical equipment[63]. - The global pharmaceutical market is expected to continue stable growth due to economic development and an aging population, with China recognized as a market with significant potential[111]. - The medical device industry in China is experiencing rapid growth, driven by national policies and increasing domestic demand[111]. Risks and Challenges - The company acknowledges risks related to macroeconomic fluctuations, policy adjustments, raw material prices, product development, and market competition[4]. - The company emphasizes the importance of investor awareness regarding potential investment risks outlined in the management discussion and analysis section[4]. - The company faces risks from market competition and must continuously optimize product structure and enhance channel networks to maintain its market position[116]. - The company has committed to avoiding any business activities that may compete with its core operations, ensuring compliance with competitive regulations[198]. - The company has faced challenges in market expansion due to intense competition and price pressures in the pharmaceutical market[199]. Research and Development - The company has established a health technology research institute to support its R&D efforts in new products and technologies[20]. - The company is focused on providing integrated solutions for medical equipment installation and maintenance in the Southern Africa region[54]. - The company aims to enhance its market share and product innovation capabilities in the orthopedic and polymer medical device sectors, gradually becoming a leader in the domestic niche market[60]. - The company has 32 authorized patents, with 25 being invention patents, and multiple new drug research projects at various clinical research stages, strengthening its core competitiveness[61]. - The company is investing heavily in R&D, with a budget allocation of 200 million RMB for the development of new medical devices and technologies[73]. - Research and development expenses increased by 30% to support innovation in medical technology[72]. - The company plans to enhance the product system of its core product, Shizhuan Jianjia, and develop long-acting formulations to increase market share[92]. - The company is advancing internationalization efforts and developing new formulations to expand market presence[92]. Governance and Compliance - The company is committed to maintaining transparency and compliance with all regulatory requirements, ensuring the accuracy of financial disclosures[190]. - The company has established a comprehensive internal governance structure involving the shareholders' meeting, board of directors, supervisory board, and management[156]. - The company has implemented a robust investor relations management system, ensuring timely communication with investors through multiple channels[124]. - The company has a dedicated financial accounting department and maintains an independent accounting system for financial management[126]. - The company has established a strong governance structure with independent directors and experienced executives overseeing operations[133]. - The company emphasizes the importance of R&D in the high-tech, high-risk pharmaceutical industry, committing to increase investment in new product development and acquisitions[116]. Environmental Responsibility - Wanbangde's wastewater discharge met the GB8978-1996 Class 3 standard, with an average COD concentration of 164.5 mg/l, well within regulatory limits[166]. - The company reported an average ammonia nitrogen concentration of 9.53 mg/l in wastewater, compliant with the relevant discharge standards[168]. - The company has implemented measures to ensure compliance with air and noise pollution standards as per relevant regulations[166]. - The company has not reported any major environmental protection issues or non-compliance with pollution discharge standards[165]. - The company has committed to sustainable development through clean production and resource conservation initiatives[178]. Employee and Talent Management - The total number of employees at the end of the reporting period is 1,569, with 1,520 from major subsidiaries and 49 from the parent company[148]. - The company has a total of 1,605 employees receiving salaries during the reporting period[148]. - The professional composition includes 706 production personnel, 263 sales personnel, 382 technical personnel, 60 financial personnel, and 158 administrative personnel[148]. - The company has established a reasonable compensation assessment system based on five principles, including market salary levels and job responsibilities[149]. - The company will continue to build its talent pool across management, marketing, and R&D teams, enhancing employee creativity and maintaining competitive vitality[114].

Group 1: Company Overview - The main business of Zhejiang Dongliang New Materials Co., Ltd. consists of profiles and panels, with profiles outperforming panels due to the rapid development of electronic reading and the shrinking paper media market [1] - The company has a stable distribution team for profiles, and despite the impact of real estate policies, the overall effect on the company is relatively small due to cost reduction and adjustment of distribution strategies [1] Group 2: Product Differentiation - Liyuan Precision's products are mainly industrial profiles used in rail transit, which belong to the current high-speed rail concept stocks, while the company's products focus on construction profiles and PS aluminum plates [1] Group 3: Future Development and Innovation - The company is currently not considering diversification into new material projects but is open to good projects that can inject new momentum into the enterprise [2] - The management is interested in projects that can derive from upstream and downstream enterprises, which are relatively innovative and easier to connect from both professional and management perspectives [2] Group 4: Automation and Cost Control - The company has introduced a three-dimensional warehouse system this year to rationally and effectively control inventory, further reducing costs and enhancing management levels [2] - Effective cost control is a competitive strategy, especially given the transportation radius limitations of profile products [2]

Group 1: Company Overview - The company primarily focuses on profiles and panels, with raw materials sourced from aluminum ingots and rods [1] - Trade business is generated by a subsidiary in Shanghai, mainly providing raw materials for the company [1] Group 2: Financial Performance - The revenue from the company's trade business is significant, with profiles outperforming panels due to the rapid growth of electronic reading and a shrinking print media market [1] - The company has a stable distribution strategy, which mitigates the impact of real estate policies [1] Group 3: Future Development - The company does not currently plan to diversify its operations but is open to good projects if they arise [2] - The management is focused on steady development, with a willingness to consider innovative projects that may arise from upstream or downstream partnerships [2] Group 4: Market Engagement - The company is attentive to capital market operations, especially given the recent activity in the capital markets [2] - The original investment bank for the company is Huaxi Securities [2]

证券代码：002082 证券简称：栋梁新材 编号：2015052601 浙江栋梁新材股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|--------------------------|----------------------------------------------------------| | | | | | | 特定对象调研 | □ 分析师会议 | | 投资者关系 | □ 媒体采访 | □ 业绩说明会 | | 活动类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | 海通证券：邱友锋 | | | 及人员姓名 | | | | 时间 | 2015 年 05 月 26 | 日 上午 | | 地点 | 公司接待室 | | | 上市公司接待 人员姓名 | | 公司董秘：袁嘉懿；财务总监：杨晓慧 | | 投资者关系活动 | 一、来访者签署《承诺书》 | | | 主要内容介绍 | | 二、就公司生产经营情况、未来发展等进行沟通交流，内 ...

证券代码：002082 证券简称：栋梁新材 编号：2015052602 浙江栋梁新材股份有限公司投资者关系活动记录表 | --- | --- | --- | |-----------------------|--------------------------|----------------------------------------------------------| | | | | | | 特定对象调研 | □ 分析师会议 | | 投资者关系 | □ 媒体采访 | □ 业绩说明会 | | 活动类别 | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 财通证券：李永良；银河证券：赵鑫 | | 及人员姓名 | | | | 时间 | 2015 年 05 月 26 | 日 下午 | | 地点 | 公司接待室 | | | 上市公司接待 人员姓名 | | 公司董秘：袁嘉懿；财务总监：杨晓慧 | | 投资者关系活动 | 一、来访者签署《承诺书》 | | | 主要内容介绍 | | 二、就公司生产经营情况、未来发展等 ...